Bioventus reports Q3 earnings, cuts 2026 revenue outlook amid strategic review
+1 new source since this summary was written
Bioventus Inc. posted third‑quarter 2026 revenue of $142.4 million and adjusted earnings of $0.17 per share, beating estimates. Net income rose to $6.0 million and adjusted EBITDA increased to $28.4 million. The company lowered its full‑year 2026 sales guidance to $590 million‑$595 million and reaffirmed adjusted EPS guidance of $0.75‑$0.79, while continuing a strategic review prompted by an unsolicited acquisition proposal.
Why it matters
The reduced revenue outlook narrows growth expectations and contributed to an 18‑19% drop in Bioventus shares, affecting investors’ valuation models. The guidance reaffirmation of adjusted EPS signals earnings resilience despite the top‑line shortfall.
Key facts
- 1Q3 2026 revenue was $142.4 million, up 3% year‑over‑year. tradingview.com
- 2Adjusted earnings per share for the quarter were $0.17. tradingview.com
- 3Net income attributable to Bioventus was $6.0 million, compared with $3.2 million a year earlier. tradingview.com
- 4Adjusted EBITDA rose 7% to $28.4 million. tradingview.com
- 5Full‑year 2026 net sales guidance was cut to $590 million‑$595 million. rttnews.com
- 6Adjusted EPS guidance for 2026 was reaffirmed at $0.75‑$0.79 per share. rttnews.com
Summary written by AlphAI AI Desk from 9 of 9 sources. Not investment advice. Figures are as stated by the linked sources.